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Compelling evidence now suggests that ab CD8 cytotoxic T lymphocytes (CTL) have an important role in
preventing human immunodeficiency virus (HIV) infection and/or slowing progression to AIDS. Here, we
describe an HIV type 1 CTL polyepitope, or polytope, vaccine comprising seven contiguous minimal HLA A2-
restricted CD8 CTL epitopes conjoined in a single artificial construct. Epitope-specific CTL lines derived from
HIV-infected individuals were able to recognize every epitope within the construct, and HLA A2-transgenic
mice immunized with a recombinant virus vaccine coding for the HIV polytope also generated CTL specific for
different epitopes. Each epitope in the polytope construct was therefore processed and presented, illustrating
the feasibility of the polytope approach for HIV vaccine design. By simultaneously inducing CTL specific for
different epitopes, an HIV polytope vaccine might generate activity against multiple challenge isolates and/or
preempt the formation of CTL escape mutants.
A considerable body of compelling indirect evidence sug-
gests that cytotoxic T lymphocytes (CTL) have a role in pre-
venting or limiting (i) initial human immunodeficiency virus
(HIV) infection (36) and (ii) progression to AIDS (16). Corre-
lations between CTL activity and protection against challenge
have been observed in lentivirus models (12, 22) and in studies
of HIV-exposed but uninfected individuals (36). The inverse
correlation between viral load and CTL levels in HIV patients
also implies a significant role for HIV-specific CTL in the
control of HIV replication (31). Direct evidence for the im-
portance of CTL was recently obtained from an ovine retrovi-
rus model in which a prophylactic vaccine designed to induce
only CTL prevented the establishment of a latent infection (21).
Induction of protective HIV-specific CTL responses is com-
plicated by the presence of multiple HIV variants, any one of
which may contain mutations in the target CTL epitopes (16),
and/or by CTL escape mutants being rapidly generated follow-
ing infection (16, 29). An ideal vaccine might induce a suffi-
cient diversity of CTL specificities to ensure CTL-mediated
protection against all or most of the potential variants within
HIV challenge inocula and perhaps also preempt the genera-
tion of CTL escape mutants. Vaccines containing multiple
recombinant antigens (10) may be able to induce CTL popu-
lations sufficiently diverse to be capable of cross-recognizing
multiple isolates (15); however, even if homology sufficient to
make such an approach feasible existed, highly variant epitopes
may dominate at the expense of relatively conserved, protec-
tive subdominant epitopes (30). A CTL epitope-based ap-
proach has the advantage of being able to focus immunity
toward protective, perhaps less variant, epitopes. Sequences
outside the CTL epitope regions, which might adversely affect
the immune response (7, 17, 20), can also be avoided. How-
ever, an epitope-based approach would be of advantage only if
multiple CTL epitopes covering a range of epitopes could be
simultaneously codelivered to induce a defined spectrum of
CTL specificities. The polyepitope, or polytope, approach rep-
resents a strategy whereby multiple contiguous minimal CTL
epitopes can be delivered as a single artificial construct (1, 14,
19, 38, 40, 41). Here, we demonstrate the immunogenicity of
an HIV polytope vaccine containing multiple contiguous HLA
A2-restricted HIV CTL epitopes from a range of HIV anti-
gens. The vaccine construct was recognized by human HIV-
specific CTL and raised multiple independent CTL responses
in HLA A2-transgenic mice. Thus, apart from offering a con-
siderable reduction in size compared to a recombinant multi-
antigen construct, the polytope approach represents an attrac-
tive strategy for CTL-based HIV vaccine design.
MATERIALS AND METHODS
HIV polytope and other recombinant vaccinia viruses. The HIV polytope
recombinant vaccinia virus (rVV.HIV.pt) was constructed as follows. A synthetic
oligonucleotide fragment (Fig. 1) was constructed from three 70-mer and one
72-mer synthetic oligonucleotides by the splicing-by-overlap-extension method
and PCR (40, 41). The nucleic acid sequence of the fragment contained (from
the 59 end) a BamHI restriction site, a Kozac sequence, a methionine start codon,
sequences corresponding to seven contiguous minimal HLA A2 HIV CTL epi-
topes (Table 1), and a stop codon and a SalI site at the 39 end. The amino acid
sequences of the CTL epitopes were converted to DNA sequences by using
universal codon usage, but inclusion of restriction sites was avoided. Dimers were
made of synthetic oligonucleotides 1-2 and 3-4 (0.4 mg of each) in 40-ml reaction
mixtures containing standard 13 Pfu PCR buffer, 0.5 mM deoxynucleoside
triphosphates, and 1 U of cloned Pfu DNA polymerase (hot start at 94°C) with
the following thermal program: 94°C for 10 s, 52°C for 20 s, and 72°C for 20 s for
five cycles. At the end of five cycles the PCR program was paused at 72°C and
20-ml aliquots of the two dimer reaction mixtures were mixed and subjected to a
further five cycles (94°C for 10 s, 48°C 20 s, and 72°C for 20 s). The reaction
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mixture was resolved on a 3% agarose gel, the 220-bp fragment was excised, and
the agarose was removed by microcentrifugation through filter paper. Two 20-
mer oligonucleotide primers (Fig. 1) were used to amplify by PCR the full-length
product for 25 cycles at an annealing temperature of 50°C. The full-length
gel-purified PCR fragment was cloned into the EcoRV site of pBluescript II
KS(2) and checked by sequencing. The insert was then subcloned behind the
vaccinia virus p7.5 promoter in the plasmid shuttle vector pPS 7.5 A with BamHI
and SalI. Construction of the recombinant vaccinia virus was then performed by
marker rescue recombination as described previously (8), by insertion of the
fragment into the f region of a thymidine kinase-negative vaccinia virus, followed
by plaque purification and selection with methotrexate.
Recombinant vaccinia virus containing HIV nef and pol expressed p27 Nef,
and the reverse transcriptase and integrase of the LAI strain of HIV (Trans-
gene, Strasbourg, France) were made available via the Programme Reactifs
de L’ANRS. The control vaccinia virus, rVV.Cont, coded for ovalbumin or the
murine polytope (40).
PCR and RT-PCR of rVV.HIV.pt-infected cells. CV1 cells (2.5 3 106) were
infected with rVV.HIV.pt (multiplicity of infection 5 5) and stored overnight,
and the RNA was extracted and reverse transcribed as described previously (26).
A control sample was also prepared without reverse transcriptase (RT). DNA
was extracted from a parallel culture of rVV.HIV.pt-infected CV1 cells with a
blood kit (Qiagen, Hilden, Germany). PCR was performed in a 20-ml volume
containing 1 ml of cDNA or DNA (or an equivalent volume of the control
samples) and 0.5 ml each of forward and reverse 20-bp primers (Fig. 1) (20 mM).
The reaction mixture was as described previously (26). An initial denaturation at
95°C for 2 min was followed by 30 cycles of PCR (95°C for 10 s, 55°C for 10 s, and
72°C for 50 s) and a 10-min extension at 72°C. PCR products were resolved on
a 2% agarose gel. The '220-bp fragments were excised, purified (Wizard puri-
fication kit; Promega, Madison, Wis.), and sequenced.
Human CTL lines. Blood was obtained from HIV-infected patients at the
Infectious Diseases Unit, Royal Brisbane Hospital. Most of the patients were
receiving highly active antiretroviral therapy (HAART) at the Infectious Dis-
eases Unit. HLA A2-positive individuals were identified by fluorescence-acti-
vated cell sorter analysis of peripheral blood mononuclear cells (PBMC) with an
HLA A2-specific mouse monoclonal antibody derived from the supernatant of
the hybridoma line ATCC HBT82, B87.2, followed by fluorescein isothiocyanate-
labelled anti-mouse F(ab9)2 (Silenus, Melbourne, Australia). Cells were fixed in
fresh 2% paraformaldehyde in phosphate-buffered saline prior to analysis.
PBMC from HLA A2 HIV-infected individuals were prepared by standard
Ficoll-Paque gradient separation, and half of the cells were sensitized with the
peptides indicated below (see Fig. 3 and Table 2) (Chiron Technologies, Clayton,
Australia) (50 mg/ml, 1 h at 37°C, followed by one wash). The sensitized PBMC
were added back to the remaining cells in a 24-well plate to 1 3 106 to 2 3 106
cells/ml (effector-to-stimulator ratio, 1:1). The cells were cultured in RPMI 1640
medium supplemented with 10% fetal calf serum (QIMR), 2 mM glutamine
(ICN Biomed. Aust. Pty. Ltd., Seven Hills, Australia), and 100 mg of streptomy-
cin per ml and 100 IU of penicillin per ml (CSL Ltd., Melbourne, Australia).
Interleukin-7 (IL-7) (300 IU/ml; Sigma, St. Louis, Mo.) was added on day 0, and
IL-2 (10 IU/ml; kindly provided by Cetus Corp., Emeryville, Calif.) was added on
day 3. The bulk effectors were used in standard 6-h 51Cr release assays on days
10 to 12, unless stated otherwise. Partial medium changes were performed when
required. Some cultures were maintained by weekly restimulations with HLA A2
lymphoblastoid cells that were peptide sensitized (10 mg/ml, 37°C for 1 h,
washed, and irradiated [8,000 rads]; responder-to-stimulator ratio ' 20:1).
Fewer than seven CTL bulk cultures (one for each peptide) were set up when
PBMC were limiting, and for these cases, restimulation with SLYNTVATL was
always included.
The target cell for the epitope-specific bulk CTL effectors was an Epstein-Barr
virus (B95.8)-transformed lymphoblastoid cell line (LCL) from an unrelated
homozygous HLA A2 healthy individual (HLA A21 LCL). HLA A21 LCLs
were either (i) infected (multiplicity of infection, 10) overnight with rVV.HIV.pt,
a recombinant vaccinia virus coding for the specified HIV antigen, a control re-
combinant vaccinia virus expressing ovalbumin, or an unrelated polytope con-
struct (rVV.Cont) (40) prior to 51Cr labelling or (ii) sensitized with peptide (10
mg/ml) at the same time as 51Cr labelling followed by two washes before use in
the 51Cr release assays. HLA A21 LCLs were used as cold target inhibitors at a
cold-to-hot ratio of 40:1.
Vaccination and CTL assays with HHD transgenic mice. Transgenic HHD
mice have a transgene comprising the a1 (H) and a2 (H) domains of HLA A2
linked to the a3 transmembrane and cytoplasmic domains of H-2Db (D), with
the a1 domain linked to human b2 microglobulin. This transgene was introduced
into murine b2 microglobulin and H-2Db double knockout mice; thus, the only
major histocompatibility complex (MHC) molecule expressed by the HHD
mouse was the modified HLA A2 molecule (32).
For the first experiment, six HHD mice were vaccinated intraperitoneally with
5 3 107 PFU of rVV.HIV.pt. After 3 weeks splenocytes were harvested and
pooled, and 5 3 106 splenocytes were restimulated with 1 3 106 lipopolysaccha-
ride blasts per 24-well plate (42). The lipopolysaccharide blasts were sensitized
with peptide (10 mg/ml for 1 h at 37°C), irradiated (3,000 rads), and washed twice
prior to use. Cells were cultured in RPMI 1640 medium (Gibco) supplemented
with 10% fetal calf serum (QIMR), 2 mM glutamine (Sigma), 5 3 1025 M
b-mercaptoethanol (Sigma), and antibiotics as described above. On day 4, 1 ml
of medium containing 5 IU of recombinant human IL-2 (Cetus) per ml was
added. On day 6 the cultures were used as effectors in standard 6-h 51Cr release
assays against EL4S3-RobHHD target cells (32), which were sensitized with the
indicated peptide (10 mg/ml) at the same time as being radiolabelled and were
washed twice prior to use.
For the DNA prime boost experiment mice were anesthetized with 100 ml of
a solution containing ketamine (10 mg/ml), xylazine (2 mg/ml), and water (4:1:1)
and were given 100 mg (50 mg into each quadriceps muscle) of either pJWHIV
(n 5 3) or a control plasmid, pJW4303 (27) (n 5 3) followed after 14 days with
an identical booster injection. After another 14 days the mice received rVV.
HIV.pt. Three weeks later the splenocytes were restimulated and 51Cr release
was performed as described above, except that splenocytes from each animal
were restimulated separately. Plasmid preparation was undertaken by using the
EndoFree Plasmid Maxi kit (Qiagen). pJWHIV was generated by subcloning the
HIV polytope insert from the HIV polytope pBluescript (see above) into
pJW4303 (27) with HindIII and EcoRI.
RESULTS
Confirmation of the polytope sequence and transcription of
the polytope insert. rVV.HIV.pt was constructed to contain a
synthetic insert (Fig. 1) coding for seven HIV HLA A2 CTL
epitopes (Table 1). The epitopes were selected from the list of
optimal HLA A2 CTL epitopes described by Brander and
Walker (2), excluding the more variant epitopes from env, and
they included the relatively conserved gp120 epitope described
by Dupuis et al. (9).
Direct sequencing of the insert in rVV.HIV.pt was used to
confirm the presence of an uncorrupted polytope insert in the
recombinant vaccinia virus. PCR of viral DNA extracted from
rVV.HIV.pt-infected cells generated an '220-bp fragment
(Fig. 2, lane E), the expected size of the insert (Fig. 1). A water
control for the PCR of viral DNA is shown in Fig. 2, lane D.
Sequencing of the '220-bp fragment gave the expected nucle-
otide sequence, shown in Fig. 1.
Polytope proteins have been very difficult to detect with
antibody probes, possibly due to their lack of structure and re-
sulting poor stability (40). RT-PCR was thus used to show ap-
propriate transcription of HIV polytope mRNA by rVV.HIV.
TABLE 1. HLA A2-restricted HIV epitopes in the polytopea
Epitope (positions) Sequence
Nef (157–166) ................................................................PLTFGWCYKL
Pol (346–354) .................................................................VIYQYMDDL
Gag (77–85)....................................................................SLYNTVATL
Nef (180–189) ................................................................VLEWRFDSRL
Pol (476–484) .................................................................ILKEPVHGV
gp120 (120–128).............................................................KLTPLCVTL
Nef (190–198) ................................................................AFHHVAREL
a Epitopes were selected from those described by Brander and Walker (2) and
Dupuis et al. (9). The more variable epitopes from env were not included.
FIG. 1. HIV polytope insert. The first epitope and then every second CTL
epitope are underlined.
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pt-infected cells (Fig. 2, lane B). A control for the RT-PCR
without RT is shown in Fig. 2, lane C.
Following infection, rVV.HIV.pt thus transcribed an HIV
polytope mRNA coding for seven HIV CTL epitopes.
Epitope-specific CTL lines from HIV patients recognize the
HIV polytope construct. CTL from 14 HLA A2 HIV patients
(Table 2) were separately restimulated in vitro with up to seven
peptide epitopes (Table 1) to generate epitope-specific bulk
CTL cultures. CTL cultures capable of recognizing at least one
of the seven epitopes were generated from seven HLA A2 HIV
patients (Fig. 3; Table 2). CTL cultures specific for more than
one epitope were derived from the PBMC of five patients (Fig.
3; Table 2), with PBMC from H10 generating cultures specific
for all seven epitopes (Fig. 3). The lower number of patients
responding to SLYNTVATL in this study than in previous
studies (3) may reflect the fact that nearly all the patients in
this study were on HAART therapy.
The peptide-restimulated bulk cultures from the remaining
seven HIV patients failed to generate significant peptide-spe-
cific activity; however, only three peptides could be tested for
five of these patients (Table 2). An example of the data derived
from seven negative bulk cultures of the PBMC of one such
individual, H28, is shown to illustrate the specificity of the in
vitro restimulation protocol (Fig. 3). Two HLA A2 HIV-sero-
negative controls (HC1 and HC2) and three HIV-seropositive
non-HLA A2 individuals (H12, H16, and H22) (Table 2) gave
results essentially similar to those for H28 (data not shown),
further demonstrating the specificity of the peptide restimula-
tion protocol. Failure to generate epitope-specific CTL lines
does not mean that the individuals did not have CTL specific
for the corresponding antigen. Most HIV patients have CTL
responses to a least one, and usually multiple, antigens (36).
Detection of such CTL would require the use of antigen or
HIV restimulation protocols, rather than the peptide restimu-
lation used in this study.
The CTL effectors, which showed lysis against peptide-sen-
sitized target cells (Fig. 3), also lysed target cells infected with
rVV.HIV.pt (Fig. 3), illustrating that each epitope in the HIV
polytope was individually processed and presented. Further-
more, in cases where sufficient bulk effectors were available,
the CTL lines were also shown to be able to lyse LCLs infected
with recombinant vaccinia virus coding for the whole antigen
from which each respective epitope was derived (Fig. 3).
HHD mice vaccinated with the HIV polytope generated CTL
specific for multiple epitopes. To determine whether the HIV
polytope construct was capable of raising CTL responses in
vivo, HHD transgenic mice were vaccinated with rVV.HIV.pt,
and the splenocytes were restimulated in vitro and used to kill
peptide-sensitized target cells (Fig. 4A). CTL responses to SL
YNTVATL, ILKEPVHGV, KLTPLCVTL, and AFHHVAR
EL were generated. CTL responses to the remaining epitopes
could not be generated in these mice by rVV.HIV.pt immuni-
zation (Fig. 4A and data not shown). The data illustrated that
the HIV polytope vaccine was able to induce in vivo CTL
responses to multiple HLA A2 HIV CTL epitopes.
To determine whether polytope CTL responses could be
enhanced by using strategies combining DNA priming and
boosters with recombinant vaccinia virus, as described previ-
FIG. 2. Agarose gel of HIV polytope PCR products from cDNA (lane B) and
viral DNA (lane E) derived from rVV.HIV.pt-infected cells. Lanes A and F, 1-kb
markers (Gibco BRL, Gaithersburg, Md.); lane B, RT-PCR of the HIV polytope
mRNA; lane C, RT-PCR control without RT; lane D, PCR control with water as
template; lane E, PCR of viral DNA. Molecular size markers indicated by
arrowheads are (from the top) 394, 344, 298, and 220 bp.
TABLE 2. Summary of PBMC donor characteristics and CTL response(s)a
Donor HLA Age (yr) CD4 count(106)/liter
RNA
copies/ml
Date of HIV
infection HIV stage CTL response(s)
H07 A2 34 260 1 3 105 4/1992 II 1/3 (VLE)
H08 A2 50 200 ,400 2/1984 II 0/3
H09p A2 41 380 1.3 3 105 1985 II 0/3
H10 A2 34 330 8.2 3 103 1985 IV C1 7/7b
H11 A2 50 320 2 3 104 1989 IV C1 0/3
H17p A2 44 700 1.1 3 104 2/1996 II 0/3
H18p A2 47 610 1.2 3 105 1985 II 0/3
H19 A2 35 90 1.3 3 105 12/1993 IV C1 2/7 (PLT, VIY)
H21 A2 47 440 ,400 1986 II 2/7 (SLY, KLT)
H24 A2 48 300 580 1988 II 1/7 (SLY)
H27 A2 48 440 5.3 3 103 1/1991 II 3/7 (SLY, VIY, ILK)
H28 A2 41 60 1.3 3 105 1994 IV C 0/7
H30 A2 65 250 ,400 5/1997 IV C 0/7
H33 A2 35 510 1.5 3 103 2/1997 II 3/7 (SLY, KLT, AFH)
H12 Not A2 37 350 ,400 1995 III 0/3
H16 Not A2 44 300 ,400 9/1997 II 0/3
H22 Not A2 32 520 ,400 9/1996 IV C1 0/1
HC1 A2 46 0 0/7
HC2 A2 37 0 0/7
a CTL response(s) is given as the number of epitopes for which specific CTL activity could be generated per the number of epitopes tested (first three amino acids
of the epitope(s) for which a response was seen). Date of HIV infection is given as year or month/year. HIV staging is based on the Centers for Disease Control and
Prevention’s surveillance case definition for AIDS. Donors HC1 and HC2 are healthy HIV-seronegative controls. p, not on HAART therapy at the time that blood was
taken. The HAART treatment unresponsiveness of this cohort was similar to that described previously for patients with a history of extended treatment (34).
b Responses to all seven epitopes shown in Fig. 3.
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ously for whole-antigen-based vaccines (24, 35, 37), mice were
immunized with a DNA vaccine coding for the HIV polytope
and were then given a booster with rVV.HIV.pt. No significant
improvement in the responses to epitopes which failed to gen-
erate a response following rVV.HIV.pt immunization (Fig.
4A) was observed following prime boost vaccination (Fig. 4B).
The responses to SLYNTVATL, ILKEPVHGV, KLTPLCV
TL, and AFHHVAREL were, however, significantly enhanced
(an average of 2.4-fold at an effector-to-target ratio of 10:1,
P 5 0.008) by prime boost strategies (Fig. 4B). CTL responses
to polytope vaccines can therefore also be enhanced by DNA
prime-plus-poxvirus boost strategies.
DISCUSSION
Here, we demonstrate the feasibility of delivering multiple
HLA A2 HIV CTL epitopes with a polytope vaccine construct.
Each epitope in the polytope construct was recognized by CTL
lines from HIV patients, and the polytope vaccine induced
multiple epitope-specific responses in HHD transgenic mice.
The DNA prime-plus-virus vector boost strategy (24, 35, 37)
also improved CTL responses when applied to polytope vac-
cines.
Potential competition and/or immunodominance phenom-
ena (30, 45) did not appear to interfere significantly with si-
multaneous presentation of, and priming by, the multiple HLA
A2 epitopes within the polytope construct. Factors intrinsic to
the epitope, such as MHC binding affinity, can determine the
immunodominance of an epitope (45). For instance, the im-
munodominant SLYNTVATL (3) binds well to HLA A2 (44),
whereas the subdominant AFHHVAREL (3) binds poorly to
HLA A2 (23). However, the subdominance of an epitope can
often be ascribed to inefficient proteolytic liberation of the
epitope from the full-length protein (45). Such processing con-
straints are less likely to operate for polytope proteins, since
these proteins appear to be rapidly degraded (40, 41) and the
epitopes in the polytope are not flanked by poorly cleaved
glycine or proline residues (13, 38, 41). The subdominance of
AFHHVAREL may in part also reflect inefficient processing,
since it appears to be codominant when presented in a poly-
tope construct (Fig. 4). An ability to mitigate against domi-
nance effects and generate multiple codominant responses may
emerge as an important attribute of polytope vaccines.
A controversy over the HLA A2 restriction of AFHHVA
REL was recently reported, based on the inability of this epi-
tope to bind to HLA A2 efficiently in in vitro binding assays (4,
23). Two HIV-infected HLA A2 individuals recognized the
AFHHVAREL epitope in this study, and rVV.HIV.pt vacci-
nation induced AFHHVAREL-specific CTL in HHD mice,
supporting the original contention that this epitope is re-
FIG. 3. Epitope-specific CTL lines derived from PBMC of HIV-infected
individuals (H28, H10, H19, H21, and H33) used as effectors against (i) HLA
A21 LCLs sensitized with the indicated peptide (black squares) or not sensitized
(white squares) (columns headed “Peptide”), (ii) HLA A21 LCLs infected with
rVV.HIV.pt (black squares) or a control recombinant vaccinia virus (white
squares) (columns headed “Polytope”), and (iii) HLA A21 LCLs infected with
rVV.nef or rVV.pol (black squares) or a control recombinant vaccinia virus
(white squares) (column headed “Antigen”). The epitope listed on the left of
each row was used to restimulate the bulk cultures, which were used to generate
the data in that row. Bulk cultures from each individual were separately restim-
ulated with the indicated peptide, split, and used against peptide and polytope
and sometimes against whole antigen expressing target cells. A summary of
patient data is shown in Table 2. The negative results, for patient H28, are shown
to illustrate the specificity of the in vitro restimulation protocol.
FIG. 4. Data from HHD mice immunized with HIV polytope vaccines. (A)
Mice were immunized with rVV.HIV.pt, and pooled splenocytes were restimu-
lated in vitro with each of the indicated peptides and used as effectors against
target cells sensitized with the same peptide (black squares) or not sensitized
(white squares). (B) Mice were immunized with two injections, either of DNA
vaccine coding for the HIV polytope followed by rVV.HIV.pt (DNA/rVV) or of
a control DNA plasmid followed by rVV.HIV.pt (rVV). Splenocyte populations
from each mouse were individually restimulated with each peptide and used as
effectors against target cells sensitized with peptide and not sensitized. (Thus, the
first six bars represent restimulation and lysis with PLTFGWCYKL.) Results
were calculated as follows: percent lysis of target cells sensitized with peptide 2
percent lysis of target cells not sensitized (6 standard error). DNA vaccination
alone produced only weak CTL responses ranging from 5 to 10% (data not shown).
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stricted by HLA A2 (18). The relatively conserved gp120 CTL
epitope, KLTPLCVTL, was recognized by three patients, sug-
gesting that this also is a commonly recognized HLA A2-
restricted epitope (9).
The HHD mouse system clearly represents an ideal model
for preclinical and quality control testing of vaccines designed
to induce HLA A2-restricted CTL responses in humans. The
inability of HLA A2-transgenic mice to respond to some epi-
topes has been reported previously (44) and may reflect a
limited T-cell receptor (TCR) repertoire educated on the HLA
A2 transgene in these animals (32). Murine TAP proteins are
more selective than their human equivalents (28), and other
murine proteins involved in processing may also be inefficient
at delivering some peptides for HLA binding (5, 33). Such
factors may result in inefficient processing of certain polytope
epitopes but may also limit the diversity of self-epitopes loaded
onto HLA A2 in the thymus in HHD mice. The latter would
reduce the diversity of the peripheral TCR repertoire educated
on HLA A2 (11). Other factors are clearly also involved, since
deletion of murine MHC expression in HHD mice appears to
increase the TCR repertoire over that found in A2Kb trans-
genic mice (32), which retain murine MHC (10a, 44).
A prophylactic HIV polytope vaccine might ultimately con-
tain a series of epitopes covering the diversity of HLA alleles
in any target population and might also contain a number of
common epitope variants. In a therapeutic setting, a cocktail of
four single HLA polytope vaccines might be used to cover the
four HLA alleles of any given individual patient. Several hu-
man delivery modalities vectors might be envisaged for HIV
polytope constructs, perhaps in conjunction with prime boost
and/or cytokine codelivery strategies (25, 41). These vectors
include DNA-based vaccination (41, 43), avipoxvirus (6, 24),
and/or modified vaccinia virus Ankara (13, 19, 37, 39).
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